Profound Medical Corp.: Form 40-F for the period ended Dec 31, 2020
Filed with the SEC on Mar 2, 2021 and accepted by EDGAR at Mar 2, 2021, 16:31 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2020-01-01 to 2020-12-31 | $7.3m | ifrs-full:Revenue |
| Cost of revenue | 12 months2020-01-01 to 2020-12-31 | $3.8m | ifrs-full:CostOfSales |
| Gross profit | 12 months2020-01-01 to 2020-12-31 | $3.5m | ifrs-full:GrossProfit |
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$18.9m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $45.0k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$21.6m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$20.6m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2020-12-31 | $83.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2020-12-31 | $97.7m | ifrs-full:CurrentAssets |
| Total assets | At period end2020-12-31 | $104.6m | ifrs-full:Assets |
| Current liabilities | At period end2020-12-31 | $4.8m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2020-12-31 | $7.3m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $97.3m | ifrs-full:Equity |
| Shares outstanding | At period end2020-12-31 | 20,208,948 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001104659-21-030782. Last ingested by Listed: Nov 12, 2026, 18:12 ET. Listed shows no prices and gives no investment advice.